Environmental, Social, Governance Facebook Twitter LinkedIn Sanofi’s social impact strategy aims to build a healthier, more resilient world by ensuring access to healthcare for the world’s poorest people, and bringing a much needed focus to the development of treatment for childhood cancer. Integrated into the company’s Play to Win business strategy, Sanofi’s commitment to society will continue the fight against infectious diseases such as sleeping sickness and polio, while accelerating its goals to reduce the environmental impact of its products and its worldwide operations. Key to tackling the global challenges that face society are its people, who each have a role to play in building a diverse and inclusive workplace. Our reporting principles are based on the Global Reporting Initiative (GRI) standards, under the “Core” option. Sanofi is also a signatory of the United Nations Global Compact. Sanofi publishes an Integrated Report based on the International Integrated Reporting Council (IIRC) framework. It presents, in a synthetic manner, the Group’s strategy for creating short, mid- and long-term value (financial and extra-financial) for the company and its stakeholders. Sanofi also publishes in its French registration document (Document d’Enregistrement Universel) a chapter on Corporate Social Responsibility (Chapter 4) which includes our Statement of Extra Financial Performance (DPEF). An English translation of this chapter is available below. CSR indicators and the auditors’ report are reported in the factsheet CSR Indicators Table and Auditor’s Report, see below. Other reference documents and factsheets are available in the Document Center of the “Our Responsibility” section (see below). SASB Index Download Quick links At the heart of Sanofi Integrated Report 2020 START THE EXPERIENCE 2020 Declaration of Extra-Financial Performance DOWNLOAD Access to all factsheets Our value creation Our contribution to the UN SDG Recognition for our extra-financial performance Sanofi’s performance is recognized through our inclusion in the most important international Socially Responsible Investment (SRI) indices including: Dow Jones Sustainability Index (DJSI) World (Bronze Class): reference index in sustainable Development FTSE4Good (Financial Times Stock Exchange) Access to Medicine Index (ATM) Stoxx® Global ESG Leaders indices Extra-financial performance SANOFI RANKINGS & SCORES - 2020 DJSI Included in 2020 DJSI World for the 14th consecutive year Included in the DJSI Europe for the 2nd consecutive year Score 84/100 #4 among 83 pharmaceuticals companies MSCI Score: BBB (scale from CCC to AAA) #5 among the 6 largest pharmaceutical companies Sustainalytics Score 24.4 Medium Risk (scale from 0 to 40+ / lower is better) #12 among 401 pharmaceutical companies ISS-ESG Score: B (Prime status) (scale from D- to A+) Among the 3 industry leaders within 391 pharmaceutical companies FTSE4Good Score: 4.2/5 (Higher is better) CDP Climate Change Score: A- CDP Water Score: A ATM index #5 among 20 pharmaceutical companies Contacts The Corporate Social Responsibility department, in coordination with the Investor Relations department, is in charge of the information analyzed by socially responsible investors and rating agencies which assess companies according to social, environmental, economic and governance criteria. Sanofi Investor Relations Tel: +33 (0)1 53 77 45 45 e-mail: investor.relations (at) sanofi.com Follow us Sanofi on Twitter Sanofi TV on YouTube Sanofi On LinkedIn Sanofi on Instagram Sanofi RSS feeds Contact Legal notice Privacy & Data Protection Cookies policy Corporate code of ethics Our publications Sitemap Our websites Accessibility: partial compliance © Sanofi 2004-2021 - All rights reserved